Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK

International Journal of Clinical Practice

Volumn 58, Issue 6, 2004, Pages 581-586

  Papazisis, Konstantinos T ^a   Habeshaw, T ^b   Miles, David W ^a   Leonard, Robert ^c   Jones, Alison ^d   Twelves, Chris ^e   Coleman, Robert ^f   Makris, Andreas ^g   Earl, Helena ^h   Highley, Martin ⁱ   Price, Chris ^j   McKinna, Fiona ^k   Perren, Tim ^l   Le Vay, John ^m   McAleer, A ⁿ   Houston, Steve ^o   Crawford, Michael ^p   Johnston, Steve ^q   Howell, A ^r   Wardley, Andrew ^r   Harris, A ^s   O'Reilly, S ^t   O'Byrne, Ken ^u   Verrill, Mark ^v   Hickish, Tamas ^w   Mansi, Janine L ^x   Barrett Lee, P J ^y   Davidson, Neville ^z   Stein, Rob ^aa   Rowland, Chris ^ab   Symmonds, Peter ^ac   Bailey, Nigel ^ad   Chan, S ^ae   Soukop, Mike ^af   more..

^a GUY S HOSPITAL   (United Kingdom)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^f WESTON PARK HOSPITAL   (United Kingdom)

^g MOUNT VERNON HOSPITAL   (United Kingdom)

^h ADDENBROOKE S HOSPITAL   (United Kingdom)

ⁱ NINEWELLS HOSPITAL   (United Kingdom)

^j BRISTOL ROYAL INFIRMARY   (United Kingdom)

^k MAIDSTONE HOSPITAL   (United Kingdom)

^l ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^m IPSWICH HOSPITAL   (United Kingdom)

ⁿ BELFAST CITY HOSPITAL   (United Kingdom)

^o ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^p AIREDALE GENERAL HOSPITAL   (United Kingdom)

^q ROYAL MARSDEN HOSPITAL   (United Kingdom)

^r CHRISTIE HOSPITAL   (United Kingdom)

^s CHURCHILL HOSPITAL   (United Kingdom)

^t CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^u LEICESTER ROYAL INFIRMARY   (United Kingdom)

^v NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^w ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^x ST GEORGE S HOSPITAL   (United Kingdom)

^y VELINDRE CANCER CENTRE   (United Kingdom)

^z NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^aa MIDDLESEX HOSPITAL   (United Kingdom)

^ab ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^ac SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^ad TORBAY HOSPITAL   (United Kingdom)

^ae NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^af GLASGOW ROYAL INFIRMARY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIPODOPHYLLOTOXIN; NAVELBINE; PACLITAXEL; TRASTUZUMAB; VINCA ALKALOID;

ADVANCED CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; HEALTH CARE ACCESS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IN VITRO STUDY; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SUPRAVENTRICULAR TACHYCARDIA; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 3242876330     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00203.x     Document Type: Review

References (36)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
2. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9: 1165-72.
3. Chazin VR, Kaleko M, Miller AD, Shalmon DJ. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 1992; 7: 1859-66.
4. HER2 monoclonal antibody in patients with HER-2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-44.
5. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48.
6. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
7. Hancock MC, Langton BC, Chan T et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cells lines. Cancer Res 1991; 51: 4575-80.
8. Pietras RJ, Fendly BM, Chazin VR et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9: 1829-38.
9. Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for the treatment of breast cancers. Oncogene 1999; 18: 2241-51.
10. Pegram MD. Docetaxel and Herceptin: foundation for future strategies. Oncologist 2001; 6 (Suppl. 3): 22-5.
11. Konecny G, Pegram MD, Beryt M et al. Therapeutic advantage of chemotherapy drugs in combination with Herceptin® against human breast cancer cells with HER2-Neu overexpression. Breast Cancer Res Treat 1999; 57: 114. [Abstract 467].
12. Merlin J-L, Barberi-Heyob M, Bachmann N. In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer lines. Ann Oncol 2002; 13: 1743-8.
13. Baselga J, Norton L, Albanell J et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825-31.
14. HER2 monoclonal antibody plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659-71.
15. Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19: 2587-95.
16. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
17. Robert N, Leyland-Jones B, Asmar L et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002; 76 (Suppl. 1): S37. [Abstract 35].
18. Pienkowski T, Fumoleau P, Eiermann W et al. Taxotere, cisplatin and Herceptin (TCH) in first-line HER2 positive metastatic breast cancer patients, a phase II pilot study by the Breast Cancer International Research Group (BCIRG 101). Proc Am Soc Clin Oncol 2001; 20. [Abstract 2030].
19. Slamon DJ, Patel R, Northfelt R et al. Phase II pilot study of Herceptin combined with taxotere and carboplatin (TCH) in metastatic breast cancer patients overexpressing the HER2-Neu proto-oncogene a pilot study of the UCLA network. Proc Am Soc Clin Oncol 2001; 20. [Abstract 193].
20. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-30.
21. Jahanzeb M, Mortimer JE, Yunus F et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2 (+) metastatic breast cancer. Oncologist 2002; 7: 410-7.
22. Chan A, Untch M, Petruzelka L et al. Multinational phase II study of Navelbine and Herceptin as first-line therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2002; 76 (Suppl. 1): S112. [Abstract 434].
23. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol 2002; 29 (Suppl. 11): 38-43.
24. Nabholtz J-MA, Reese DM, Lindsay M-A, Riva A. Docetaxel in the treatment of breast cancer: An update of recent studies. Semin Oncol 2002; 99 (Suppl. 2): 28-34.
25. Baselga J, Seidman AD, Rosen PP, Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 1997; 11 (Suppl. 2): 43-8.
26. Montemurro F, Choa G, Faggiuolo R et al. Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer. Am J Clin Oncol 2003; 26: 95-7.
27. Montemurro F, Choa G, Faggiuolo R et al. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Proc Am Soc Clin Oncol 2003; 22. [Abstract 191].
28. Esteva FJ, Valero, V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 1800-8.
29. Raab G, Brugger W, Harbeck N et al. Multicenter randomized phase II study of docetaxel given q 3 w vs q 1 w plus trastuzumab as first-line therapy for HER2 overexpressing adjuvant anthracycline pretreated metastatic breast cancer. Breast Cancer Res Treat 2002; 76 (Suppl. 1): S114. [Abstract 443].
30. Meden H, Beneke A, Hesse T et al. Weekly intravenous recombinant humanized anti-HER2 monoclonal antibody (trastuzumab) plus docetaxel in patients with metastatic breast cancer: a pilot study. Proc Am Soc Clin Oncol 2001; 20. [Abstract 1987].
31. Malik U, Sparano J, Manalo J et al. Phase II trial of weekly docetaxel (taxotere) alone or in combination with trastuzumab (Herceptin) in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19. [Abstract 586].
32. Kuzur M, Albain K, Huntigton M et al. A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2. Proc Am Soc Clin Oncol 2000; 19. [Abstract 512].
33. Uber KA, Nicholson BP, Thor AD et al. A phase II trial of weekly docetaxel and Herceptin as first- or second-line treatment in HER2 over-expressing metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20. [Abstract 1949].
34. Nicholson B, Thor A, Goldstein L et al. Weekly docetaxel and rhumabher2 combination therapy as first- or second-line treatment for metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19. [Abstract 549].
35. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
36. Extra J-M, Cognetti F, Chan S et al. Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastatic breast cancer. Eur J Cancer 2003; 1 (Suppl. 5): S202.